14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
EVEX vs SRTA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Strata Critical Medical, Inc. (SRTA) is the stronger overall head-to-head candidate over Eve Holding, Inc. (EVEX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). EVEX carries a Unified Composite Score of 41.3/100 (SELL) at $1.70 (N/M Forward P/E, 0.0% operating margin), whereas SRTA carries 29.9/100 (SELL) at $5.38 (71.1x Forward P/E, -4.7% operating margin).
Composite vs. Pillar Nuance: While EVEX currently prints a higher short-term Unified Composite Score (41.3/100 SELL vs. SRTA 29.9/100 SELL), SRTA captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-4.7% vs. 0.0% operating margin) and revenue trajectory (+50.3% vs. +0.0% YoY).
Defensive Composite Rating Caution: Although SRTA compares more favorably head-to-head, both EVEX (41.3/100 SELL) and SRTA (29.9/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: EVEX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.8); meanwhile SRTA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 54.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EVEX vs SRTA. Trailing 12-month operating profitability (EVEX 0.0% vs SRTA -4.7%) and valuation multiples (EVEX N/M vs SRTA 71.1x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Care Facilities value chain with $515.4M market capitalization and -4.7% operating margin.
OpEx & R&D Reinvestment26.3% of Rev ($74M)
90D Engineering Disclosures0 Published
Investor FAQ EVEX vs SRTA Key Questions & Quantitative Answers
As of Nov 16, 2026, Strata Critical Medical, Inc. (SRTA) is the stronger overall head-to-head candidate over Eve Holding, Inc. (EVEX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). EVEX carries a Unified Composite Score of 41.3/100 (SELL) at $1.70 (N/M Forward P/E, 0.0% operating margin), whereas SRTA carries 29.9/100 (SELL) at $5.38 (71.1x Forward P/E, -4.7% operating margin). Composite vs. Pillar Nuance: While EVEX currently prints a higher short-term Unified Composite Score (41.3/100 SELL vs. SRTA 29.9/100 SELL), SRTA captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-4.7% vs. 0.0% operating margin) and revenue trajectory (+50.3% vs. +0.0% YoY). Defensive Composite Rating Caution: Although SRTA compares more favorably head-to-head, both EVEX (41.3/100 SELL) and SRTA (29.9/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: EVEX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.8); meanwhile SRTA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 54.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SRTA leads the Growth & Scale pillar: EVEX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with SRTA at +50.3% YoY revenue growth and +0.0% YoY earnings growth on $281M TTM revenue (21.6% gross margin, -4.7% operating margin). On trailing 12-month operating scale, EVEX generates N/A in USD-normalized revenue versus $281M for SRTA. In operating R&D and SG&A reinvestment, EVEX deploys N/A (0 90-day corporate R&D disclosures) versus 26.3% of Rev ($74M) (0 disclosures) for SRTA.
SRTA screens cheaper on headline valuation multiples. EVEX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas SRTA trades at 71.1x Forward P/E, 138.9x Trailing P/E, N/M PEG, and 1.7x EV/Revenue (-0.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EVEX (-300.9% ROE) versus SRTA (-7.5% ROE) capital efficiency.
In options market volatility and institutional positioning, EVEX carries 72.3% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.71β · 96% Vol realized risk). By comparison, SRTA carries 61.9% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.43x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.97β · 82% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.